Evidence map›Paper›PMID 36248619›Full record

ArticleEJHaem2022

COVID-19 systematic screening of asymptomatic haematopoietic stem cell donors: Less if often more.

Lucie Blandin, Elise Tolmer, Eric Hermet, Aurélie Ravinet, Amélie Brebion, Richard Lemal, Paul Rouzaire

Abstract readCase Reports
In one paragraph

Article in EJHaem, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lucie BlandinHistocompatibility and Immunogenetics Laboratory Clermont-Ferrand University Hospital Clermont-Ferrand France.
Elise TolmerHistocompatibility and Immunogenetics Laboratory Clermont-Ferrand University Hospital Clermont-Ferrand France.
Eric HermetCellular Therapy and Clinical Haematology Department Clermont-Ferrand University Hospital Clermont-Ferrand France.
Aurélie RavinetCellular Therapy and Clinical Haematology Department Clermont-Ferrand University Hospital Clermont-Ferrand France.
Amélie BrebionVirology Laboratory Clermont-Ferrand University Hospital Clermont-Ferrand France.
Richard LemalHistocompatibility and Immunogenetics Laboratory Clermont-Ferrand University Hospital Clermont-Ferrand France.ORCID https://orcid.org/0000-0002-5767-1628
Paul RouzaireHistocompatibility and Immunogenetics Laboratory Clermont-Ferrand University Hospital Clermont-Ferrand France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

From COVID pandemic spread until now, many HSCT unrelated donor registries recommend as a precaution a systematic COVID-19 testing for all donors during the precollection time. Literature is quite poor to support this systematic attitude. We report one sibling allogeneic HSCT which we proceeded despite a positive COVID test on related asymptomatic donor and summarize the all seven cases reported until now. We suggest to question this systematic COVID testing, two years after pandemic began, when there is no systematic testing on other blood products received during all the haematological malignancies treatment process.

Indexed as

coviddonorsHSC TRANSPLANTATION

Identifiers

PMID36248619
PMCPMC9538191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.